Abstract: Disclosed is a self-invertible inverse latex including, as an inverting agent, surfactant species of the polyglycerol ester family; the use thereof as a thickening and/or emulsifying and/or stabilising agent for a cosmetic, dermopharmaceutical or pharmaceutical topical composition, and cosmetic, dermopharmaceutical or pharmaceutical topical compositions containing same. Also disclosed is a new surfactant composition containing polyglycerol esters.

Abstract: A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) wherein R1 and R2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and An+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that An+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H2NR1R2+?OC?ONR1R2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.

Abstract: Provided are: a core-corona polymer particle excellent in emulsion stability and feeling of use, and a raw material for a cosmetic and an oil-in-water emulsion cosmetic comprising the particle. Certain embodiments of the present invention provides a raw material for a cosmetic comprising a core-corona polymer particle obtained by radical-polymerizing a polyethylene oxide macromonomer represented by formula (1) and one or two or more of hydrophobic monomers represented by formulas (2) and (3) under conditions (A) to (D).

Abstract: Provided are a raw material for a cosmetic and an oil-in-water emulsion cosmetic comprising a core-corona polymer particle excellent in emulsion stability and feeling of use. Certain embodiments of the present invention provides a raw material for a cosmetic, comprising a core-corona polymer particle dispersion obtained by radical-polymerizing a polyethylene oxide macromonomer represented by formula (1) and one or two or more of hydrophobic monomers represented by formulas (2) and (3) under conditions (A) to (D).

Abstract: A skincare composition containing plant extracts and a preparation method thereof. The skincare composition containing plant extracts, comprising, by weight percentage, the following components: 0.2-0.5% of a complex plant extract, 1-3.5% of a carbohydrate derivative, 50-60% of a thickener, 1.5-4% of a first skin conditioner, 0.1-0.3% of a second skin conditioner, 2-3% of a third skin conditioner, 3-5% of a first moisturizer, 4-6% of a second moisturizer, and the balance of deionized water.

Abstract: The present invention discloses a toothpaste, comprising a toothpaste body and an extract of Chinese medical composition which is included in a content of 2%-5%, the Chinese medical composition comprises by weight parts: Acorus calamus 20-30, ATRACTYLODES 22-30, Chrysanthemum 20-25 and Ginger 15-25.

Abstract: A composition for restorative vaginal lubrication and a method of use thereof facilitates enhances the overall vaginal health. The composition includes a quantity of water, a quantity of glycerin, a quantity of cetearyl alcohol, a quantity of glyceryl stearate, a quantity of avocado oil, a quantity of squalene oil, a quantity of lecithin, a quantity of benzoin oil, a quantity of xanthan gum, a quantity of citric acid, a quantity of potassium sorbate, a quantity of Dehydroepiandrosterone (DHEA), a quantity of elderberry extract, a quantity of damiana extract, a quantity of progesterone, a quantity of pomegranate oil, and a quantity of sodium benzoate. The composition is homogeneously mixed into a vaginal salve that may be both externally and internally applied with the vaginal area in order to moisturize the vaginal area and enhance sexual pleasure during sexual activity. The vaginal salve also promotes blood circulation for the vaginal area.

Abstract: An innovative fast-absorbing cosmetic oil is created through an acacia gum or other tree gum diffusion process. The lipophilic molecules from the polysaccharide chain of the tree gum chemically bond to the lipid molecules of the cosmetic oil. This diffusion process results in a composition of the fast-absorbing cosmetic oil that is substantially soft and velvety. The fast-absorbing cosmetic oil thus creates immediate plumping of the skin, fast absorption of oil into the skin without a greasy residue, skin tightening and lifting, and many other benefits to skin. Additionally, methods of making the composition of the fast-absorbing cosmetic oil are provided with or without the use of water and a broken emulsion process.

Abstract: A herbal composition for increasing hair volume comprises a first medicinal material including Lilum, Scutellaria barbata D. Don, Carica papaya Linn, Lonicera japonica, or any combinations thereof; a second medicinal material including Rehmannia glutionsa, Cuscuta chinensis, and Crocus sativus; a third medicinal materials including Platycladus orientalis having its bark of root and leaf combined with Black sesame, Platycladus orientalis having its bark of root and leaf combined with Morus having its fruits, root, leaf, and twig, Purple grape, or any combinations thereof; wherein the first medicinal material weighs 2˜40%, the second medicinal material weighs 2˜40%, and the third medicinal material weighs 20˜96% of the total weight of the herbal composition.

Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

Abstract: Human warts have been the subject of many treatment options. Most of the effective strategies involve invasive procedures or painful treatments. The goal of this treatment is to find a topical application of a compound that will remove the infected tissue without significant discomfort to the patient. The present invention effects the treatment by using a polymerizing compound that forms a boundary between the hyperkeratotic layer of infected epithelial cells and the healthy skin cells. This modality is both painless and does not harm healthy cells.

Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Abstract: Disclosed herein are coatings made from a biocompatible controlled release polymer and an active component. The active component can be, for example, an antimicrobial agent, an immune modulating agent, a cell signaling factor, or a growth factor. The coating has micrometer and nanometer scale features on the surface thereof.

Abstract: The present invention provides an infusion preparation that is inhibited from generation of unwanted insoluble matter after mixing of two liquids of the infusion preparation in long-term storage. More specifically, the present invention provides an infusion preparation comprising two chambers separated by a communicably openable partition, a first chamber containing a first-chamber infusion comprising a fat emulsion and further comprising at least one member selected from the group consisting of amino acids that have a buffer action, divalent organic acids, and trivalent organic acids, a second chamber containing a second-chamber infusion comprising an amino acid and at least calcium as an electrolyte, wherein a total concentration of the amino acids that have a buffer action, divalent organic acids, and trivalent organic acids in the first-chamber infusion is 0.15 to 0.5 g/L, and a mixture of the first- and second-chamber infusions has a pH of 6.

Abstract: Disclosed herein are segmented, EVA intravaginal rings that release 17?-estradiol and progesterone with specific pharmacokinetics useful for treating, ameliorating, and preventing symptoms associated with menopause and vulvar and vaginal atrophy.

Abstract: Provided herein are compositions and methods of ameliorating pharmaceutical aversiveness via salt. In one aspect, a composition is provided comprising Praziquantel, and an effective amount of Na Gluconate which suppresses bitter taste of orally administrated Praziquantel. Additionally, a composition is provided comprising Piperaquine and an effective amount of KOH which suppresses aversiveness of orally administrated Piperaquine.

Abstract: Disclosed are effective fixed dose oral testosterone undecanoate compositions for use in regimens without dose titration and methods for treatment of patients in need of testosterone replacement therapy. Also disclosed are criteria for continuation and discontinuation of such regimens, based on single serum T concentration levels measured at a steady state at predetermined times after initiation of said regimen and at a predetermined number of hours after administration of a morning dose of the regimen.

Abstract: The invention is directed to a sublingual tablet comprising sildenafil citrate in an amount comprised between 10 mg and 150 mg, and a non-ionic surfactant in an amount comprised between 20 and 100% by weight of the amount of sildenafil citrate, wherein the nonionic surfactant is a polyethoxylated compound comprising a polar and a non-polar part, wherein the polar part of the molecule comprises from 3 to 8 ethoxy groups and the non-polar part is a C4-C20 alkyl group or a C7-C20 aryl group. The sublingual tablet is prepared by a process that comprises the following steps: introducing sildenafil citrate into a mixer; adding to the mixer containing sildenafil citrate the nonionic surfactant in at least three aliquots and mixing for 5 minutes after the addition of each aliquot. The tablet according to the invention is characterized by a high concentration of sildenafil, is easy to take, and with a good taste in the mouth.

Abstract: The present invention provides a salivator that is in a form for use in the mouth (a form for intraoral use), or in a form for use by oral administration (a form for oral administration). The salivator can be prepared by using enzymatically modified isoquercitrin, or a combination of enzyme-modified isoquercitrin and a thickening polysaccharide. The present invention further provides an additive that is useful for preparing an oral composition (a food or beverage, a pharmaceutical product for oral administration) (an additive for an oral composition) and that can impart at least one effect selected from the group consisting of a salivation-promoting effect, a deglutition-improving effect (swallowing-assisting effect), and a mastication-improving effect (chewing-assisting effect) to the oral composition. The additive can be prepared by using a combination of enzymatically modified isoquercitrin and a thickening polysaccharide.

Abstract: The presently disclosed subject matter is directed to a system and method of preparing personalized nutritional and/or pharmaceutical formulations using additive manufacturing technology. Active pharmaceutical or dietary supplement ingredients are suspended in thixotropic stable carrier medias. The thixotropic suspensions are deposited onto a surface of a solid substrate, which can be a snack bar or small wafer used as a mechanical carrier. The disclosed system enables each additive active ingredient to be variably dosed based on a formula that is determined for each specific individual and manufactured on demand. Once the active ingredients are deposited on substrate, the entire assembly can be enrobed with one or more edible solid coatings to seal the active ingredients and provide taste-masking agent characteristics to the assembly.

Abstract: This disclosure relates to metal nanoparticle compositions and methods for treating respiratory infections associated with cystic fibrosis. An amount of nonionic, ground state metal nanoparticles are administered to a patient via inhalation. The metal nanoparticles have properties that enable effective transport through the viscous mucus layer to the epithelia and surrounding tissues, killing or deactivating infecting microbes at the targeted respiratory tissue and throughout the overlying mucus layer.

Abstract: Product for the therapeutic treatment for the prevention and cure of oral cavity diseases of teeth and dental implants including a mixture in a polyvinyl alcohol aqueous solution, of one or more polyacids or their salts, of one or more antiseptics and/or anti-inflammatories, capable of obtaining in situ a protective and adhesive barrier, capable of facilitating the bioavailability of the aforementioned medicinal products, antiseptics and anti-inflammatories.

Abstract: A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa as active ingredients and one or more excipients. Once dispersed in an aqueous medium, melevodopa is completely dissolved, and carbidopa is present as nanoparticles.

Abstract: Methods of treatment to prevent NTM microaggregate formation using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Abstract: A liposome composition with adipocyte specificity comprises a shell formed by a liposome material, and a ligand material bound to a surface of the shell. The ligand material is a plurality of long chain fatty acids, and the liposome composition recognizes and binds to an adipocyte by the plurality of long chain fatty acids.

Abstract: Disclosed herein are methods, processes, compositions, and kits for generating bone graft materials for use at a site of bone defect that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide. Also disclosed herein are methods, processes, compositions, and kits for enhancing mammalian bone marrow cells that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide.

Abstract: Provided herein are compositions comprising exosomes comprising an immunomodulatory molecule, e.g., ICOSL or OX40L, on their surface. Further provided are methods of using such exosomes for the treatment of diseases requiring immunomodulation, such as cancer, autoimmune disease, or infectious disease.

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins.

Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.

Abstract: The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2a receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about ?40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.

Abstract: The present invention provides an innovative combination of biomaterials, multifunctional polymers, able to structure themselves at the site of action. The innovative combination of biomaterials of the invention is formulated in a solid composition and can be used as a versatile delivery vehicle or carrier in many pharmaceutical fields. The solid composition comprising the combination of biomaterials of the invention is provided to target delivery for medical purposes in humans.

Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Abstract: A polymer mixture includes 10 to 90 wt. % of polymer 1 and 10 to 90 wt. % of polymer 2, the total being 100 wt. %. Polymer 1 is polymerized from (a1) 70-95 wt. % of C1-C12 alkylester of (meth)acrylic acid, and (b1) 5-30% wt. % of C2-C8 alkyl ester of (meth)acrylic acid with a quaternary cationic group in the alkyl group. Polymer 2 is polymerized from (a2) 70-95 wt. % of C1-C12 alkylester of (meth)acrylic acid, and (c2) 5-30 wt. % of C2-C6 hydroxy-alkylester of (meth)acrylic acid. Monomers (a1) and (b1) add up to 98-100 wt. %, and most preferred to 100 wt. %. Monomers (a2) and (c2) add up to 98-100 wt. %, most preferred to 100 wt %.

Abstract: The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

Abstract: The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: at least one liver-targeting ligand, such as C2-alpha galactose; at least one payload ligand comprising a bioactive agent, such as maytansinoid DM1; and at least one dilution ligand comprising a poly(ethyleneglycol) (PEG) moiety, such as PEG COOH. Also provided are pharmaceutical compositions comprising the nanoparticle, and uses of the nanoparticle in methods of treatment of liver disorders, including liver cancers such as hepatocellular carcinoma (HCC).

Abstract: Nanoparticles comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer and compositions, especially topical compositions, comprising the nanoparticles. The compositions can be used as topical formulations for ameliorating pain, including for diabetic patients with peripheral neuropathy.

Abstract: This disclosure provides nanoparticle compositions comprising nucleoside or nucleotide prodrugs, their use as medicinal agents, and processes for their preparation. The disclosure also provides for the use of the nanoparticle compositions described herein as medicaments and/or in the manufacture of medicaments for the treatment of a variety of diseases, including cancer and viral infections. Provided in one aspect is a composition comprising nanoparticles, wherein the nanoparticles comprise a prodrug of a nucleoside or nucleotide, and a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier comprises albumin.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer, wherein the active agent-containing layer comprises a therapeutically effective amount of the active agent and at least one silicone acrylic hybrid polymer, and C) a skin contact layer.

Abstract: A living body-adhesive sheet of the present disclosure includes a living body-adhesive film and a support. The living body-adhesive film has a thickness of 5 ?m or less and contains cellulose. The support supports the living body-adhesive film. The support is formed of a material in which a hydrogen bonding component ?H in a Hansen solubility parameter is 2 to 20 MPa1/2.

Abstract: The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ER?) ligand.

Abstract: Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.

Abstract: A cannabinoid formulation including a carbon-based antioxidant. Preferably, the formulation is a colloid including C60 and cannabinoids in a lipid-based excipient. The formulation improves shelf life of cannabinoids and inhibits degradation of the cannabinoids over time due to oxidation. The present invention further sequesters, neutralizes, or inhibits, oxidative free radicals in vivo. The action of the C60 prepares the body on a cellular level to enhance the bioactivity of the cannabinoids. The function of the C60 in combination with cannabinoids greatly reduces inflammation, improves metabolism, inhibits free radical degradation of telomeres, and has many other health benefits. The C60 in combination with the cannabinoids enhances the function of the cannabinoids by improving latency and efficacy in vivo.

Abstract: The present invention provides methods and compositions for the treatment of mucopolysaccharidoses (MPS).

Abstract: Colloidal antiseptic compositions for treating wounds and/or for use in surgical operations are provided. The compositions form an elastic air- and water-permeable biodegradable film on the wound surface and have antiseptic, hemostatic, anti-inflammatory, wound-healing, and especially anesthetic and antitoxic effects. The compositions include a collagen hydrolysate, one or more salts of alginic acid and one or more antiseptics, and additionally include unithiol and dimethylsulfoxide. The compositions may also optionally include one or more anesthetics.

Abstract: A curcumin-containing composition has improved oral absorbability. An oral ingestion composition contains: (A) solid curcumin containing an amorphous body and/or an analog thereof; and (B) a solid water-soluble polymer which becomes viscous in an aqueous medium having a pH of 5 or more.

Abstract: The invention relates to stable preparations of thymoquinone and methods of making and administering stable preparations of thymoquinone. Embodiments of the methods provide compositions comprising thymoquinone with phosphatidylcholine and/or guggulsterol and/or guggulsterol derivatives and/or sodium cholesteryl sulfate, in tablet, capsule, gel, or ointment forms, and method of administering the preparations.

Abstract: An object of the invention is to provide a gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester. Abnormal gene expression due to, for example, oxidative stress can be treated, improved, and/or prevented, and diseases caused by the abnormal gene expression can be treated, improved, and/or prevented. A gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester are provided and are useful for treating, improving, and/or preventing the symptom caused by the abnormal gene expression, that is, excessive expression or suppression of expression.

Abstract: Provided are methods of treating a neurological or psychiatric disorder in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof in combination with an amount of one or more compounds effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.

Abstract: The present invention relates to treatment of inflammatory diseases with agents that target different phases of the life cycle of Chlamydia spp. In particular, the invention features the use of a combination of one or more of taurine, dimethylglycine, and trimethylglycine with one or more of a rifamycin antibiotic, a macrolide antibiotic, and a tetracycline antibiotic for treating inflammatory diseases resulting from Chlamydial infection.